Liang Jian-wei, Dong Shu-xiao, Zhou Zhi-xiang, Tian Yan-tao, Zhao Dong-bing, Wang Cheng-feng, Zhao Ping
Department of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Chin Med J (Engl). 2008 Oct 5;121(19):1900-5.
Gallbladder carcinoma is rare and associated with dismal outcomes. Radical surgery is the only curative treatment, and options for adjuvant therapy remain limited. This study aimed to determine the factors influencing outcome of treatment in patients with gallbladder carcinoma, and to identify the patients who might benefit from radical surgery and adjuvant therapy.
Medical records and follow-up histories of 150 patients with gallbladder carcinoma who had undergone surgery between April 1980 and December 2005 were retrospectively reviewed. The factors predictive for the survival of the patients were identified using multivariate analysis.
Surgery for gallbladder cancer was associated with an overall 5-year survival rate of 26.2%. After curative resection (40% of the patients), the 5-year survival rate was 60.3%. The patients who underwent R0 resection had a significantly longer median survival (97.3 months) than those who had R1/R2 resection (8.3 months) or only laparotomy (3.7 months) (P < 0.0001). Univariate analysis showed that resectability, American Joint Committee on Cancer staging, tumor grade, adjuvant therapy, jaundice at presentation, depth of tumor invasion, lymph node involvement, distant metastasis, and carcinoembryonic antigen level were statistically significant predictors for survival. Multivariate analysis revealed American Joint Committee on Cancer staging and resectability were independent prognostic factors for survival. The patients who underwent noncurative resection might benefit from adjuvant therapy (median survival, 12.4 months vs 7.2 months, P = 0.006).
Favorable survival rate can be achieved after curative resection, even for selected patients with advanced disease. Adjuvant therapy may improve the survival of patients with gallbladder carcinoma.
胆囊癌较为罕见,预后较差。根治性手术是唯一的治愈性治疗方法,辅助治疗的选择仍然有限。本研究旨在确定影响胆囊癌患者治疗结果的因素,并确定可能从根治性手术和辅助治疗中获益的患者。
回顾性分析1980年4月至2005年12月期间接受手术的150例胆囊癌患者的病历和随访记录。采用多因素分析确定患者生存的预测因素。
胆囊癌手术患者的总体5年生存率为26.2%。根治性切除术后(40%的患者),5年生存率为60.3%。接受R0切除的患者中位生存期(97.3个月)明显长于接受R1/R2切除(8.3个月)或仅接受剖腹手术(3.7个月)的患者(P<0.0001)。单因素分析显示,可切除性、美国癌症联合委员会分期、肿瘤分级、辅助治疗、就诊时黄疸、肿瘤浸润深度、淋巴结受累、远处转移和癌胚抗原水平是生存的统计学显著预测因素。多因素分析显示,美国癌症联合委员会分期和可切除性是生存的独立预后因素。接受非根治性切除的患者可能从辅助治疗中获益(中位生存期,12.4个月对7.2个月,P=0.006)。
即使是部分晚期患者,根治性切除术后也可获得良好的生存率。辅助治疗可能提高胆囊癌患者的生存率。